Aion Therapeutic Inc. Logo

Aion Therapeutic Inc.

ANTCF

(2.2)
Stock Price

0,00 USD

-148.56% ROA

264.2% ROE

-3x PER

Market Cap.

6.294.757,46 USD

197.01% DER

0% Yield

-788.87% NPM

Aion Therapeutic Inc. Stock Analysis

Aion Therapeutic Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aion Therapeutic Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 PBV

With a remarkably low PBV ratio (-0.4x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-50%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

5 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

6 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

7 ROE

The stock's ROE indicates a negative return (-27.28%) on shareholders' equity, suggesting poor financial performance.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Aion Therapeutic Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aion Therapeutic Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Hold

Aion Therapeutic Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aion Therapeutic Inc. Revenue
Year Revenue Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 888.172 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aion Therapeutic Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 0
2018 306.764 100%
2019 15.990 -1818.47%
2020 18.401 13.1%
2021 0 0%
2022 953.000 100%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aion Therapeutic Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 51.273
2018 127.503 59.79%
2019 1.024.956 87.56%
2020 579.121 -76.98%
2021 2.166.750 73.27%
2022 1.131.070 -91.57%
2023 1.304.828 13.32%
2023 587.834 -121.97%
2024 1.158.488 49.26%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aion Therapeutic Inc. EBITDA
Year EBITDA Growth
2017 -121.923
2018 -131.077 6.98%
2019 -1.700.769 92.29%
2020 -885.590 -92.05%
2021 -2.651.893 66.61%
2022 -2.753.620 3.69%
2023 -1.304.828 -111.03%
2023 -1.067.206 -22.27%
2024 -897.040 -18.97%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aion Therapeutic Inc. Gross Profit
Year Gross Profit Growth
2017 0
2018 -2.000 100%
2019 0 0%
2020 -111.053 100%
2021 -128.130 13.33%
2022 -65.293 -96.24%
2023 0 0%
2023 -17.301 100%
2024 354.992 104.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aion Therapeutic Inc. Net Profit
Year Net Profit Growth
2017 -1.506.748
2018 -140.114 -975.37%
2019 -4.933.645 97.16%
2020 -672.832 -633.27%
2021 -8.265.148 91.86%
2022 -3.818.390 -116.46%
2023 3.232.372 218.13%
2023 -256.658 1359.41%
2024 -1.511.816 83.02%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aion Therapeutic Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aion Therapeutic Inc. Free Cashflow
Year Free Cashflow Growth
2017 -117.958
2018 -332.870 64.56%
2019 -3.268.801 89.82%
2020 -756.379 -332.16%
2021 -3.578.321 78.86%
2022 -1.346.890 -165.67%
2023 -41.397 -3153.59%
2023 -81.151 48.99%
2024 243.238 133.36%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aion Therapeutic Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 -117.958
2018 -332.870 64.56%
2019 -1.318.459 74.75%
2020 -551.750 -138.96%
2021 -2.133.479 74.14%
2022 -1.346.890 -58.4%
2023 -41.397 -3153.59%
2023 -81.151 48.99%
2024 243.238 133.36%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aion Therapeutic Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 0
2018 0 0%
2019 1.950.342 100%
2020 204.629 -853.11%
2021 1.444.842 85.84%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aion Therapeutic Inc. Equity
Year Equity Growth
2017 -217.029
2018 -312.128 30.47%
2019 2.638.081 111.83%
2020 2.134.249 -23.61%
2021 397.464 -436.97%
2022 -2.406.609 116.52%
2023 -2.725.826 11.71%
2023 -1.530.789 -78.07%
2024 1.032.828 248.21%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aion Therapeutic Inc. Assets
Year Assets Growth
2017 19.471
2018 8.986 -116.68%
2019 4.108.313 99.78%
2020 3.335.793 -23.16%
2021 1.603.503 -108.03%
2022 150.144 -967.98%
2023 210.672 28.73%
2023 694.153 69.65%
2024 5.887.752 88.21%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aion Therapeutic Inc. Liabilities
Year Liabilities Growth
2017 236.500
2018 321.114 26.35%
2019 1.470.232 78.16%
2020 1.201.544 -22.36%
2021 1.206.039 0.37%
2022 2.556.753 52.83%
2023 2.936.498 12.93%
2023 2.224.942 -31.98%
2024 4.854.924 54.17%

Aion Therapeutic Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-3x
Price To Sales Ratio
28.35x
POCF Ratio
41.87
PFCF Ratio
54.55
Price to Book Ratio
4.68
EV to Sales
35.94
EV Over EBITDA
-8.55
EV to Operating CashFlow
69.15
EV to FreeCashFlow
69.15
Earnings Yield
-0.33
FreeCashFlow Yield
0.02
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.02
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
-0.07
ROE
0.91
Return On Assets
-5.2
Return On Capital Employed
0.33
Net Income per EBT
1
EBT Per Ebit
4.74
Ebit per Revenue
-1.66
Effective Tax Rate
0.04

Margins

Sales, General, & Administrative to Revenue
3.19
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.03
Operating Profit Margin
-1.66
Pretax Profit Margin
-7.89
Net Profit Margin
-7.89

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.31
Return on Tangible Assets
-1.49
Days Sales Outstanding
209.32
Days Payables Outstanding
6942.52
Days of Inventory on Hand
1094.95
Receivables Turnover
1.74
Payables Turnover
0.05
Inventory Turnover
0.33
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
0
Interest Debt per Share
0.01
Debt to Equity
1.97
Debt to Assets
0.35
Net Debt to EBITDA
-1.81
Current Ratio
0.18
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
1019873
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.82
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
209383.5
Debt to Market Cap
0.32

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aion Therapeutic Inc. Dividends
Year Dividends Growth

Aion Therapeutic Inc. Profile

About Aion Therapeutic Inc.

Aion Therapeutic Inc. offer medical cannabis products in Canada. The company was formerly known as Osoyoos Cannabis Inc. and changed its name to Aion Therapeutic Inc. in August 2020. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada.

CEO
Mr. John Graham Simmonds Jr.
Employee
0
Address
45 Sheppard Avenue East
Toronto, M2N 5W9

Aion Therapeutic Inc. Executives & BODs

Aion Therapeutic Inc. Executives & BODs
# Name Age
1 Mr. Rakesh Malhotra (US), B.Com., C.A., C.P.A., CA (Canada), F.C.A., F
Chief Financial Officer
70
2 Mr. John Graham Simmonds Jr.
Chief Executive Officer, Chief Operating Officer & Executive Vice Chair of Board
70

Aion Therapeutic Inc. Competitors